Atrial Fibrillation
A stroke occurs when the blood supply to part of the brain is interrupted. Patients with an irregular heart beat (known as atrial fibrillation) are at increased risk of stroke. Preventing stroke in these patients is a key focus of our cardiovascular team. Boehringer Ingelheim developed the first non-vitamin K antagonist oral anticoagulant (NOAC) to protect patients with non-valvular atrial fibrillation against stroke, advancing anticoagulation care.
Latest Articles
Artrial Fibrillation
PCI with Stenting in AF Patients
Animation explaining percutaneous coronary intervention with stenting in atrial fibrillation
Artrial Fibrillation
AF Patient Preferences Survey - Introduction
Introduction, objectives and overview of the patient population in the AF Patient Preferences Survey
Artrial Fibrillation